Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 231
- Registration Number
- NCT00156806
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT00137488
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Using Intensity-Modulated Radiation Therapy to Permit Sparing of Parotid Gland Function
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 130
- Registration Number
- NCT00137475
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment
Terminated
- Conditions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 120
- Registration Number
- NCT00131612
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins
Terminated
- Conditions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT00131586
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer
- Conditions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 104
- Registration Number
- NCT00131599
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Phase 1
Terminated
- Conditions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 50
- Registration Number
- NCT00130936
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Tomotherapy in Patients With Benign Brain Tumour
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 49
- Registration Number
- NCT00128986
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT00129012
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00127816
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
© Copyright 2024. All Rights Reserved by MedPath